MBX Biosciences Names Cornelius to Board

James Cornelius

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Carmel-based MBX Biosciences Inc. has named James Cornelius to its board of directors. He previously served as chief executive officer and chairman of the board of Bristol Myers Squibb. 

Cornelius also served as chief financial officer at Eli Lilly and Co. from 1983 until 1995. From 2009 until 2017, he served as chairman of the board of Mead Johnson Nutrition when it was acquired by Reckitt Benckiser for $16 billion. He also served as board chairman and chief executive officer of Guidant from November 2005 to April 2006.

Cornelius earned a bachelor’s degree magna cum laude and an MBA from Michigan State University.